Gene
MTOR
MTOR is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (26), Actionable biomarkers (10), Trial mentions (297), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention MTOR. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 95 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 7 of 8,738 | 0.08% | not measured | |
| 2025 | 10 of 8,875 | 0.11% | not measured | |
| 2024 | 12 of 8,597 | 0.14% | not measured | |
| 2023 | 12 of 8,275 | 0.15% | 237 of 11,460 | 2.07% |
| 2022 | 10 of 8,285 | 0.12% | 349 of 13,598 | 2.57% |
| 2021 | 13 of 8,692 | 0.15% | 403 of 15,045 | 2.68% |
| 2020 | 17 of 7,640 | 0.22% | 362 of 14,459 | 2.50% |
| 2019 | 10 of 7,300 | 0.14% | 303 of 12,159 | 2.49% |
| 2018 | 13 of 6,927 | 0.19% | 284 of 11,854 | 2.40% |
| 2017 | 17 of 6,558 | 0.26% | 278 of 11,595 | 2.40% |
Showing 10 of 37 years.
Assay-provider ledger (26)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| BT LAB | Reagent supplier | Clinical validation | 1 | September 01, 2025 |
| Molecular You | Diagnostic provider | Analytical validation | 1 | February 07, 2025 |
| MRM Proteomics | Reagent supplier | Analytical validation | 1 | February 07, 2025 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 1 | May 17, 2021 |
| Agilent Technologies | Reagent supplier | Analytical validation | 1 | January 24, 2017 |
Showing 5 of 26 assay-provider companies.
Actionable biomarkers (10)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| MTOR (K1771R) | EVEROLIMUS | response-associated | anaplastic oligodendroglioma | Cancer Genome Interpreter |
| MTOR (I1973F) | EVEROLIMUS | response-associated | angiosarcoma | Cancer Genome Interpreter |
| MTOR (K1771R) | EVEROLIMUS | response-associated | gastric carcinoma | Cancer Genome Interpreter |
| MTOR (N1421D) | EVEROLIMUS | response-associated | gastric carcinoma | Cancer Genome Interpreter |
| MTOR (I1973F) | EVEROLIMUS | response-associated | renal carcinoma | Cancer Genome Interpreter |
Showing 5 of 10 actionable-biomarker assertions.
Trial mentions (297)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02550639 | Trial eligibility (AACT) |
| NCT03511560 | Trial eligibility (AACT) |
| NCT01935973 | Trial eligibility (AACT) |
| NCT01154335 | Trial eligibility (AACT) |
| NCT01625156 | Trial eligibility (AACT) |
Showing 5 of 297 trial mentions.
Target-disease associations (1,257)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| Aarskog-Scott syndrome, X-linked | genetic, familial or congenital disease | Literature (Europe PMC) |
| Abdominal Aortic Aneurysm | cardiovascular disease | Literature (Europe PMC) |
| Abnormal facial shape | phenotype | Variant curation (ClinVar / EVA) |
Showing 5 of 1,257 associations.
Vendor sourcing (948)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant was observed as assumed (i.e. paternity and maternity not confirmed) de novoo (3billion dataset, PM6). It is not observed in the gnomAD v2.1.1 da... | View ClinVar record SCV002012066.1 |
| A&G Pharmaceutical (United States) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Signed informed consent/authorization is obtained prior to conducting any study-specific screening procedures. 2. 18 years of age or older. 3. Histolog... | View trial NCT05627960 |
| A&G Pharmaceutical (United States) | Trial sponsor | Mentioned in trial textTrial free-text mention | MTOR | View trial NCT05627960 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV004563782.1 |
| AVEO Oncology (United States) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Any prior systemic therapy for treatment of mRCC (including investigational or licensed drugs that target VEGF or VEGF receptors/pathway, or are mammali... | View trial NCT01673386 |
Showing 5 of 948 sourcing records.
Trial-cited literature (4,035)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| The Inflammation-Energy Metabolism Axis: A Central Driver of Sarcopenia-Osteoporosis: A Narrative Review. | Calcified tissue international | 2026 | 10 |
| Chronic Rejection Series: Heart Cardiac Allograft Vasculopathy. | Transplantation | 2026 | 3 |
| Leniolisib reduced lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome. | Journal of human immunity | 2026 | 1 |
| Pyruvate metabolism enzyme DLAT promotes tumorigenesis by suppressing leucine catabolism. | Cell metabolism | 2025 | 37 |
| Non-coding RNAs: emerging biomarkers and therapeutic targets in cancer and inflammatory diseases. | Frontiers in oncology | 2025 | 34 |
Showing 5 of 4,035 papers.
Protein variant mentions (94)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1519T | 1 | 2015 | PMID 25741868 |
| p.A1971T | 1 | 2015 | PMID 25741868 |
| p.A480S | 1 | 2015 | PMID 25741868 |
| p.A648V | 1 | 2016 | PMID 27126807 |
| p.C1483R | 2 | 2015 to 2016 | PMID 26619011, PMID 25799227 |
Showing 5 of 94 variants.
Human sample screening reference (3)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.L2383F | TCGA-LUAD | Cystic, Mucinous and Serous Neoplasms; Ductal and Lobular Neoplasms; Acinar Cell Neoplasms; Adenomas and Adenocarcinomas; Bronchus and lung | 1 | 573 | 0.17% | 0.03% to 0.98% |
| p.T1977R | TCGA-KIRC | Adenomas and Adenocarcinomas; Kidney | 2 | 536 | 0.37% | 0.10% to 1.35% |
| p.T1977R | TCGA-PRAD | Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Acinar Cell Neoplasms; Ductal and Lobular Neoplasms; Prostate gland | 1 | 500 | 0.20% | 0.04% to 1.12% |
Literature-extracted relations (1,172)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Sirolimus | Chemical | negative_correlate |
Leniolisib reduced lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome. | 2026 |
| Sirolimus | Chemical | negative_correlate |
Personalized sirolimus regimen for vascular malformations: a retrospective analysis of VASE cohort. | 2025 |
| EVEROLIMUS | Chemical | negative_correlate |
Single nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a phase 0/1 trial of recurrent high-grade glioma. | 2025 |
| Sirolimus | Chemical | negative_correlate |
Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy: a pilot study. | 2025 |
| Sirolimus | Chemical | negative_correlate |
Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer's Disease. | 2025 |
Showing 5 of 1,172 relation assertions.
Organizations publishing (1,453)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 167 | 2005 to 2026 |
| Memorial Sloan Kettering Cancer Center | Hospital | 163 | 2005 to 2025 |
| The University of Texas System | Academic | 158 | 2004 to 2025 |
| Dana-Farber Cancer Institute | Other | 120 | 2004 to 2025 |
| Harvard Medical School | Academic | 106 | 2004 to 2025 |
Showing 5 of 1,453 organizations.
Where MTOR appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
1,091 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.